Toxicities:

MHRA alert: Atezolizumab (Tecentriq) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs) (June 2021) (www.gov.uk).

ATEZOLIZUMAB

Important: Therapy notes


MHRA advice: Atezolizumab (Tecentriq) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs) (June 2021) (www.gov.uk).
NICE Guidance: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (June 2019) (www.nice.org.uk).

Risk minimisation materials

Important: Formulation and dosage details

Formulation:

Concentrate solution for infusion 840mg/14mL (hospital use only)

Dosage:

See SMC advice 1336/18, SMC2267SMC2279SMC2349, SMC2379, SMC2492.

Important: Formulation and dosage details

Formulation:

Concentrate solution for infusion 1200mg/20mL (hospital use only)

Dosage:

See SMC advice 1336/18, SMC2267SMC2279SMC2349SMC2379SMC2492.

Important: Formulation and dosage details

Formulation:

Solution for injection 1,875mg/15mL (125mg/mL) (hospital use only)

See SMC advice: 1336/18, SMC2267SMC2279SMC2349SMC2379SMC2492.

Dosage:

To be given via subcutaneous injection

AVELUMAB

Important: Therapy notes


Risk minimisation materials

Important: Formulation and dosage details

Formulation:

Concentrate for solution for infusion200mg/10mL (hospital use only)

 

Dosage:

See SMC advice 1315/182248 and 2359.

CEMIPLIMAB

Important: Therapy notes


Risk minimisation materials

Important: Formulation and dosage details

Formulation:

Solution for infusion 350mg (hospital use only)

Dosage:

See SMC advice 2216.

DOSTARLIMAB

Important: Therapy notes

Risk minimisation materials

Important: Formulation and dosage details

Formulation:

Concentrate for solution for infusion 500mg (hospital use only)

Dosage:

See SMC advice 2404, 2635.

DURVALUMAB

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Solution for infusion 50mg/ml (hospital use only)

Dosage:

See SMC advice 2156 and 2582.

IPILIMUMAB

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Concentrate for solution for infusion 5mg/mL (hospital use only)

Dosage:

See SMC advice 779/12, 997/14 and 2094.

NIVOLUMAB

Important: Therapy notes

MHRA advice: Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation (October 2019) (www.gov.uk).
MHRA advice: Nivolumab (Opdivo). pembrolizumab (Keytruda): reports of organ transplant rejection (July 2017) (www.gov.uk).


Risk minimisation materials

Important: Formulation and dosage details

Formulation:

Concentrate for solution for infusion 10mg/mL (hospital use only)

Dosage:

First choice for indication as per SMC advice 2112.
See SMC advice 1120/16,  1180/161187/161240/17, 1261/17, 1188/162153236223852394242924582503, 2519 and 2619.

Important: Formulation and dosage details

Formulation:

Solution for injection 40mg/4mL, 100mg/10mL (hospital use only)

Dosage:

See SMC advice 1144/16.

NIVOLUMAB WITH RELATLIMAB

Important: Therapy notes

Risk management materials

Important: Formulation and dosage details

Formulation:

Concentrate for solution for infusion 12mg nivolumab and 4mg relatlimab/mL (240mg/80mg in 20mL vial) (Restricted: Hospital use only)

Dosage:

As per SMC2645: first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older.

PEMBROLIZUMAB

Important: Therapy notes

MHRA advice: Nivolumab (Opdivo). pembrolizumab (Keytruda): reports of organ transplant rejection (July 2017) (www.gov.uk).

Risk management materials

Important: Formulation and dosage details

Formulation:

Concentrate for solution for infusion 25mg/mL (Restricted: hospital use only)

Dosage:

See SMC advice 1086/15, 1204/17, 1239/17, 1291/18, 1296/18, 2144, 2187, 2207, 2247, 2257, 2375, 2380, 2420, 2460, 2474, 2479, 2501, 252625382589 and 2660.

Editorial Information

Document Id: F302